image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 2.62
-3.32 %
$ 259 M
Market Cap
-5.14
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one AQST stock under the worst case scenario is HIDDEN Compared to the current market price of 2.62 USD, Aquestive Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one AQST stock under the base case scenario is HIDDEN Compared to the current market price of 2.62 USD, Aquestive Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one AQST stock under the best case scenario is HIDDEN Compared to the current market price of 2.62 USD, Aquestive Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart AQST

image
$6.0$6.0$5.5$5.5$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.515 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
57.6 M REVENUE
13.80%
-30.8 M OPERATING INCOME
-103.75%
-44.1 M NET INCOME
-460.83%
-35.8 M OPERATING CASH FLOW
-460.49%
-159 K INVESTING CASH FLOW
84.02%
83.6 M FINANCING CASH FLOW
2003.47%
11.9 M REVENUE
-12.37%
-13.6 M OPERATING INCOME
-63.80%
-17.1 M NET INCOME
-48.19%
-6.49 M OPERATING CASH FLOW
45.38%
-15 K INVESTING CASH FLOW
81.25%
157 K FINANCING CASH FLOW
1023.53%
Balance Sheet Aquestive Therapeutics, Inc.
image
Current Assets 88.2 M
Cash & Short-Term Investments 71.5 M
Receivables 7.34 M
Other Current Assets 9.33 M
Non-Current Assets 13.2 M
Long-Term Investments 0
PP&E 8.98 M
Other Non-Current Assets 4.22 M
70.54 %7.24 %9.20 %8.85 %4.16 %Total Assets$101.4m
Current Liabilities 18.9 M
Accounts Payable 10.3 M
Short-Term Debt 536 K
Other Current Liabilities 8.04 M
Non-Current Liabilities 143 M
Long-Term Debt 37.5 M
Other Non-Current Liabilities 105 M
6.37 %4.98 %23.19 %65.14 %Total Liabilities$161.6m
EFFICIENCY
Earnings Waterfall Aquestive Therapeutics, Inc.
image
Revenue 57.6 M
Cost Of Revenue 17.9 M
Gross Profit 39.7 M
Operating Expenses 70.5 M
Operating Income -30.8 M
Other Expenses 13.4 M
Net Income -44.1 M
60m60m40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)58m(18m)40m(70m)(31m)(13m)(44m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
68.95% GROSS MARGIN
68.95%
-53.46% OPERATING MARGIN
-53.46%
-76.68% NET MARGIN
-76.68%
73.37% ROE
73.37%
-43.52% ROA
-43.52%
-37.02% ROIC
-37.02%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Aquestive Therapeutics, Inc.
image
10m10m00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -44.1 M
Depreciation & Amortization 718 K
Capital Expenditures -159 K
Stock-Based Compensation 7.1 M
Change in Working Capital -9.96 M
Others -4.04 M
Free Cash Flow -35.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Aquestive Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for AQST of $8 , with forecasts ranging from a low of $7 to a high of $10 .
AQST Lowest Price Target Wall Street Target
7 USD 167.18%
AQST Average Price Target Wall Street Target
8 USD 205.34%
AQST Highest Price Target Wall Street Target
10 USD 281.68%
Price
Max Price Target
Min Price Target
Average Price Target
10109988776655443322May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 11
6. Ownership
Insider Ownership Aquestive Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
214 USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Aquestive Therapeutics: Oral Anaphylaxis NDA Opportunity Spells Buy Aquestive currently plays small ball with a handful of approved products that offer no adequate financial potential. Its recently approved Libervant, which offered greater revenue opportunity, is mired in litigation. Aquestive's Anaphylm, which is set for an imminent FDA filing, has blockbuster potential. seekingalpha.com - 3 weeks ago
Aquestive Therapeutics, Inc. (AQST) Q4 2024 Earnings Call Transcript Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q4 2024 Results Conference Call March 6, 2025 8:00 AM ET Company Participants Brian Korb - IR Dan Barber - CEO Ernie Toth - CFO Sherry Korczynski - SVP of Sales and Marketing Carl Kraus - CMO Conference Call Participants David Amsellem - Piper Sandler Francois Brisebois - Oppenheimer Kristen Kluska - Cantor Fitzgerald Jason Butler - JMP Securities Raghuram Selvaraju - HC Wainwright & Co. Gary Nachman - Raymond James Thomas Flaten - Lake Street Capital Markets James Molloy - Alliance Global Partners Operator Good day, and thank you for standing by. Welcome to the Fourth Quarter 2024 Aquestive Therapeutics Earnings Conference Call. seekingalpha.com - 1 month ago
Compared to Estimates, Aquestive Therapeutics (AQST) Q4 Earnings: A Look at Key Metrics The headline numbers for Aquestive Therapeutics (AQST) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com - 1 month ago
Aquestive Therapeutics (AQST) Reports Q4 Loss, Lags Revenue Estimates Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.12 per share a year ago. zacks.com - 1 month ago
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update WARREN, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a progress update on the key 2025 objectives previously outlined by the Company. globenewswire.com - 1 month ago
Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting WARREN, N.J., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that multiple presentations highlighting results from the investigational use of Anaphylm epinephrine sublingual film in the treatment of severe allergic reactions, including anaphylaxis, will be featured at the 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting. The meeting will take place February 28 - March 3, 2025, in San Diego, CA. globenewswire.com - 2 months ago
Aquestive Therapeutics: Five Foci For 2025 Aquestive Therapeutics' Anaphylm is nearing FDA approval, potentially disrupting the U.S. anaphylaxis market dominated by EpiPen, with peak sales estimated at $300–400M. AQST-108, a topical epinephrine gel for alopecia areata, shows promise with minimal side effects and could expedite its regulatory path, targeting a billion-dollar market. Libervant, a diazepam buccal film for cluster seizures, has gained orphan drug exclusivity, extending market exclusivity to 2031, ensuring a reliable revenue stream. seekingalpha.com - 3 months ago
Undercovered Dozen: Asbury Automotive, Globalstar, Northland Power, Aquestive Therapeutics + The 'Undercovered' Dozen series highlights 12 lesser-covered stocks, offering fresh investment ideas and sparking community discussions on their potential. Xometry's AI-driven procurement software in a specialized B2B marketplace shows high-growth potential to Bert Hochfeld, making it a promising investment. Grassroots Trading argues that Boston Scientific's acquisition of Axonics enhances its urology offerings, positioning it strongly in the sacral neuromodulation field. seekingalpha.com - 5 months ago
Aquestive Therapeutics, Inc. (AQST) Q3 2024 Earnings Call Transcript Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q3 2024 Earnings Call Transcript November 5, 2024 8:00 AM ET Company Participants Bennett Watson - IR, ICR Westwicke IR Dan Barber - CEO Ernie Toth - CFO Sherry Korczynski - SVP of Sales and Marketing Carl Kraus - CMO Steve Wargacki - CSO Conference Call Participants Roanna Ruiz - Leerink Partners David Amsellem - Piper Sandler Francois Brisebois - Oppenheimer Raghuram Selvaraju - HC Wainwright & Co. Jason Butler - JMP Securities Thomas Flaten - Lake Street Capital Markets Gary Nachman - Raymond James James Molloy - Alliance Global Partners Operator Good morning, and welcome to the Aquestive Therapeutics Third Quarter 2024 Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com - 5 months ago
Aquestive: Rare Opportunity With Dual Platform Strategy Aquestive Therapeutics specializes in innovative film-based medicines and epinephrine products & delivery. The company's PharmFilm and Adrenaverse platforms offer unique competitive advantages, making it a strong investment opportunity. A risk-adjusted valuation indicates that Aquestive is currently undervalued compared to its market price. seekingalpha.com - 5 months ago
Aquestive Therapeutics (AQST) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates Although the revenue and EPS for Aquestive Therapeutics (AQST) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com - 5 months ago
Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.03 per share a year ago. zacks.com - 5 months ago
8. Profile Summary

Aquestive Therapeutics, Inc. AQST

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 259 M
Dividend Yield 0.00%
Description Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey.
Contact 30 Technology Drive, Warren, NJ, 07059 https://www.aquestive.com
IPO Date July 25, 2018
Employees 142
Officers Ms. Sherry Korczynski Senior Vice President of Sales & Marketing Dr. Carl N. Kraus M.D. Chief Medical Officer Dr. Gary H. Slatko M.D., MBA Chief Medical Officer Ms. Lori J. Braender BSBA, Esq., J.D. Chief Legal Officer, Chief Compliance Officer &Secretary Dr. Stephen Wargacki Ph.D. Chief Science Officer Mr. Peter E. Boyd Senior Vice President of Information Technology & Human Resources Mr. Robert Charles Arnold Vice President of Finance, Controller & Assistant Secretary Mr. A. Ernest Toth Jr. Chief Financial Officer Mr. Daniel Barber Chief Executive Officer, President & Director Ms. Cassie Jung Chief Operating Officer